Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled colistimethate plus ciprofloxacin for Pseudomonas aeruginosa infection in chronic pulmonary disease
2015-003662-87Phase 2Terminated
- Sponsor
- Aarhus University Hospital
- Start
- Sep 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of colistimethate sodium, ciprofloxacin and piperacillin + tazobactam in Pseudomonas aeruginosa pulmonary infection and pneumonia (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Pseudomonas-positive sputum cultures. Started Sep 2015; status: terminated.
02
Drugs
colistimethate sodiumciprofloxacinpiperacillin + tazobactam
03
Conditions
Pseudomonas aeruginosa pulmonary infectionpneumonia
Beyond the preview
Go deeper on 2015-003662-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003662-87.